The University of California (UC), Davis Center for Translational Genomic Phenotyping (CTGP): A National Cancer Institute-Mouse Models of Human Cancer Consortium (NCI-MMHCC) Science Leadership Application will provide centralized discovery-driven in-vivo and ex-vivo phenotyping for validation of model pathology. This is predominantly centered on Cancer Biology, but Impacts Preventative Interventions, Experimental Therapeutics and Cancer Susceptibility programs as well. The application is organized in five sections. 1. As a Summary of the Research, the PI, Dr. Robert Cardiff, is a Co-Pl, Co-I and collaborator on several past and newly submitted MMHCC research projects. He Is Co-l on """"""""Goal 1"""""""" research applications submitted with Lewis Chodosh, Cory Abate-Shen, and Robert Schreiber. He has consistently provided consultation and leadership within the MMHCC Consortium with respect to phenotypes, translation of pathologic findings in the mouse to the human disease, and defining and publicizing criteria for diagnosis, staging and grading critical to the use of the mouse models in cancer biology, prevention, and experimental therapeutics. 2. The Leadership Plan will A) electronically coordinate intra-NCI-MMHCC projects in the specific research clusters of Preventative Interventions and Cancer Biology and anticipate fostering collaborations among the U0l awardees who are affiliated with these research clusters;B) foster collaborations throughout the MMHCC and with other NCI networks and consortia to delineate research resources or pilot projects that promote the cluster collaborations;and C) manage and enhance the existing NCI cancer model bioinformatics infrastructure through caELMIR with Integrated image archives of in-vivo and ex-vivo images that are accurately mapped to relevant human bioinformatics systems in collaboration. 3. The Communication and Coordination will be achieved through the informatics tools connecting the MMHCC research affiliates with the expert pathology/phenotyping resource embodied In the Academy for Genomic Pathology. This group constitutes most of the leading authorities and most experienced mouse model and comparative pathologists in the country. 4. Outreach will be achieved through symposia and workshops, as well as an open visiting trainee/ visiting professor program at the UC Davis center. In addition, the connections at UC Davis to the Mutant Mouse Regional Resource Center, and the Knockout Mouse Project Repository provide added outreach to the mouse modeling community. 5. Pre-Clinical Models Informatics for the MMHCC and the NCI has been developed, in part, by our group at UC Davis. Studies have been Initiated at UC Davis, and specific pilot projects designs demanding accurate integrated data from mouse colony management, pathology laboratory information systems, whole slide images, radiology image data and display and electronic """"""""lab notebooks"""""""" using caELMIR, caMOD, and the caBIG infrastructure. This application is uniquely relevant to the program priorities. This is a Leadership U01 centered on phenotyping and pathology, with extensive support from a host of national experts In mouse pathology, and extensive background and preliminary work In development of Informatics uniquely designed to the purposes of the MMHCC consortium

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA141582-02
Application #
7923217
Study Section
Special Emphasis Panel (ZCA1-SRLB-Q (M1))
Program Officer
Marks, Cheryl L
Project Start
2009-09-01
Project End
2014-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
2
Fiscal Year
2010
Total Cost
$741,585
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Mori, Hidetoshi; Cardiff, Robert D; Borowsky, Alexander D (2018) Aging Mouse Models Reveal Complex Tumor-Microenvironment Interactions in Cancer Progression. Front Cell Dev Biol 6:35
Mori, Hidetoshi; Chen, Jane Q; Cardiff, Robert D et al. (2017) Pathobiology of the 129:Stat1 -/- mouse model of human age-related ER-positive breast cancer with an immune infiltrate-excluded phenotype. Breast Cancer Res 19:102
Bui, Tung; Schade, Babette; Cardiff, Robert D et al. (2017) ?-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model. Proc Natl Acad Sci U S A 114:E707-E716
Turpin, J; Ling, C; Crosby, E J et al. (2016) The ErbB2?Ex16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. Oncogene 35:6053-6064
Schmitz, Jennifer; Schwab, Julian; Schwenck, Johannes et al. (2016) Decoding Intratumoral Heterogeneity of Breast Cancer by Multiparametric In Vivo Imaging: A Translational Study. Cancer Res 76:5512-22
Mori, Hidetoshi; Soonsawad, Pan; Schuetter, Louis et al. (2015) Introduction of Zinc-salt Fixation for Effective Detection of Immune Cell-related Markers by Immunohistochemistry. Toxicol Pathol 43:883-9
Chen, Jane Q; Mori, Hidetoshi; Cardiff, Robert D et al. (2015) Abnormal Mammary Development in 129:STAT1-Null Mice is Stroma-Dependent. PLoS One 10:e0129895
Fite, Brett Z; Wong, Andrew; Liu, Yu et al. (2015) Magnetic resonance imaging assessment of effective ablated volume following high intensity focused ultrasound. PLoS One 10:e0120037
Koren, Shany; Reavie, Linsey; Couto, Joana Pinto et al. (2015) PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature 525:114-8
Bao, Lei; Cardiff, Robert D; Steinbach, Paul et al. (2015) Multipotent luminal mammary cancer stem cells model tumor heterogeneity. Breast Cancer Res 17:137

Showing the most recent 10 out of 37 publications